Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | USP2 | O75604 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | DHFR | P00374 | 1/20 | 0.59 |
| ▸ | CA1 | P00915 | 1/20 | 0.59 |
| ▸ | CA2 | P00918 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | TTR | P02766 | 1/20 | 0.59 |
| ▸ | ALB | P02768 | 1/20 | 0.59 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.59 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.59 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.59 |
| ▸ | ERN1 | O75460 | 15/20 | 0.49 |
| ▸ | PIM1 | P11309 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11014814 | 0.87 | TTR (0.55) | KDM4EMEN1USP2ALDH1A1DHFR | |
| SCHEMBL868189 | 0.84 | ERN1 (0.62) | KDM4EMEN1USP2ALDH1A1DHFR | |
| SCHEMBL15372412 | 0.82 | ERN1 (0.45) | KDM4EMEN1USP2ALDH1A1DHFR | |
| SCHEMBL505574 | 0.81 | PIM1 (0.50) | KDM4EMEN1USP2ALDH1A1DHFR | |
| SCHEMBL2789137 | 0.81 | ERN1 (0.66) | ALDH1A1ERN1 | |
| SCHEMBL29694520 | 0.80 | ERN1 (0.57) | ERN1 | |
| SCHEMBL117649 | 0.80 | ERN1 (0.57) | ERN1 | |
| SCHEMBL12834085 | 0.78 | ERN1 (0.71) | MEN1USP2ALDH1A1KMT2AERN1 | |
| SCHEMBL6644760 | 0.78 | ESR1 (0.63) | KDM4ELMNAHSD17B10ERN1 | |
| SCHEMBL12395484 | 0.77 | PIM1 (0.47) | KDM4EMEN1USP2ALDH1A1DHFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5466682-A | Bone disorders | ISTITUTO GENTILI S.P.A. (IT) | 1995-11-14 | — | — | US | claimed |
| CN-113801087-B | Benzo-six-membered ring derivatives as DPP-4 inhibitors and uses thereof | 山东百极地长制药有限公司 | 2024-08-30 | — | — | CN | disclosed |
| CN-113801088-B | Benzo six-membered ring derivative and application thereof | 山东百极地长制药有限公司 | 2024-04-26 | — | — | CN | disclosed |
| US-11612598-B2 | Compounds and methods for the treatment of cancer | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2023-03-28 | — | — | US | disclosed |
| CN-113801087-A | Benzo-hexatomic ring derivative as DPP-4 inhibitor and application thereof | 山东百极地长制药有限公司 | 2021-12-17 | — | — | CN | disclosed |
| CN-113801088-A | Benzo-six-membered ring derivative and application thereof | 山东百极地长制药有限公司 | 2021-12-17 | — | — | CN | disclosed |
| WO-2021249566-A1 | BENZO SIX-MEMBERED RING DERIVATIVE AND USE THEREOF | 山东百极地长制药有限公司 | 2021-12-16 | — | — | WO | disclosed |
| EP-1893210-B1 | SELECTIVE APOPTOTIC INDUCTION IN CANCER CELLS INCLUDING ACTIVATION OF PROCASPASE-3 | UNIV ILLINOIS (US) | 2019-10-02 | — | — | EP | disclosed |
| US-20190201394-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2019-07-04 | — | — | US | disclosed |
| US-20170105989-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2017-04-20 | — | — | US | disclosed |
| WO-2010009215-A1 | NICOTINIC ACID RECEPTOR AGONIST COMPOUNDS USEFUL TO TREAT METABOLIC SYNDROMES | SCHERING CORPORATION (US) | 2010-01-21 | — | — | WO | disclosed |
| WO-2008134474-A2 | COMPOSITIONS AND METHODS INCLUDING CELL DEATH INDUCERS AND PROCASPASE ACTIVATION | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2008-11-06 | — | — | WO | disclosed |
| US-20070049602-A1 | Selective Apoptotic Induction in Cancer Cells Including Activation of Procaspase-3 | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2007-03-01 | — | — | US | disclosed |
| US-20070049602-A1 | Selective Apoptotic Induction in Cancer Cells Including Activation of Procaspase-3 | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2007-03-01 | — | — | US | disclosed |
| EP-0254354-B1 | PHARMACEUTICALLY USEFUL DERIVATIVES OF THIAZOLIDINE-4-CARBOXYLIC ACID | ZAMBON S.p.A. (IT) | 1993-03-31 | — | — | EP | disclosed |
| US-4840936-A | ANTIFLAMMATORY, ANALGESIC AGENT TO PREVENT ARRHYTHMIAS | ZAMBON S.P.A. (IT) | 1989-06-20 | — | — | US | disclosed |
| EP-0254354-A1 | Pharmaceutically useful derivatives of thiazolidine-4-carboxylic acid | ZAMBON S.p.A. (IT) | 1988-01-27 | — | — | EP | disclosed |
| US-4711879-A | IMMUNO-MODULATING ACTIVITY | CIBA-GEIGY CORPORATION (US) | 1987-12-08 | — | — | US | disclosed |
| US-4640911-A | IMMUNOSTIMULANTS, VIRICIDES SUCH AS HERPES SIMPLEX | CIBA-GEIGY CORPORATION (US) | 1987-02-03 | — | — | US | disclosed |
| EP-0163286-A2 | Acylated sugars, method for their preparation and their use | CIBA-GEIGY AG (CH) | 1985-12-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049602-A1 | Selective Apoptotic Induction in Cancer Cells Including Activation of Procaspase-3 | CASP3, CASP7, CASP6 | KDM4E 2612/4885MEN1 2100/4885USP2 1317/4885 |
| US-20190201394-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER | CASP3, BAX, CASP6 | KDM4E 1254/4885MEN1 3135/4885USP2 2600/4885 |
| US-20170105989-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER | CASP3, CASP6, CASP5 | KDM4E 529/4885MEN1 3608/4885USP2 2371/4885 |
| US-11612598-B2 | Compounds and methods for the treatment of cancer | CASP3, BAX, CASP6 | KDM4E 1254/4885MEN1 3135/4885USP2 2600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.